[BMRN] BioMarin Pharmaceutical Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 85.66 Change: 2.12 (2.54%)
Ext. hours: Change: 0 (0%)

chart BMRN

Refresh chart

Strongest Trends Summary For BMRN

BMRN is in the medium-term down -23% below S&P in 6 months and down -34% below S&P in 1 year. In the long-term up 597% in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.98% Sales Growth - Q/Q-11.95% P/E-86.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-4.46% ROE-6.74% ROI-5.17%
Current Ratio4.98 Quick Ratio4.25 Long Term Debt/Equity0.54 Debt Ratio0.13
Gross Margin82.59% Operating Margin-16.48% Net Profit Margin-20.35% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities914.79 M Cash From Investing Activities-750.87 M Cash From Operating Activities-137.81 M Gross Profit170.45 M
Net Profit-67.5 M Operating Profit-66.02 M Total Assets3.66 B Total Current Assets1.52 B
Total Current Liabilities305.51 M Total Debt655.49 M Total Liabilities1.23 B Total Revenue203.26 M
Technical Data
High 52 week106.07 Low 52 week76.01 Last close76.99 Last change0.13%
RSI33.73 Average true range2.22 Beta1.08 Volume685.95 K
Simple moving average 20 days-3.78% Simple moving average 50 days-6.13% Simple moving average 200 days-13.32%
Performance Data
Performance Week-1.09% Performance Month-6.93% Performance Quart-6.6% Performance Half-18.34%
Performance Year-25.48% Performance Year-to-date-9.58% Volatility daily1.48% Volatility weekly3.31%
Volatility monthly6.78% Volatility yearly23.47% Relative Volume211.9% Average Volume1.29 M
New High New Low


2019-11-15 04:00:00 | BioMarin Can Trade Sideways in the Near-Term, Use It as a Buying Opportunity

2019-11-14 11:01:00 | Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York

2019-11-14 08:27:00 | BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

2019-11-12 11:37:00 | Buy Big Biotech — But Not Gilead, Analyst Says

2019-11-12 10:32:00 | The Winds Have Changed for BioMarin

2019-11-12 09:30:02 | REGN or BMRN: Which Is the Better Value Stock Right Now?

2019-11-12 08:30:00 | BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019

2019-11-08 14:33:07 | Sarepta SRPT Q3 Loss Widens Y/Y, Revenues Beat Estimates

2019-11-08 10:02:02 | After son’s rare disease diagnosis, father finds hope through film festival

2019-11-06 16:05:00 | BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th

2019-10-30 09:23:01 | Can The Uptrend Continue for BioMarin Pharmaceutical?

2019-10-29 09:00:01 | BioMarin BMRN Upgraded to Buy: What Does It Mean for the Stock?

2019-10-24 12:50:04 | BioMarin's BMRN Earnings & Revenues Beat Estimates in Q3

2019-10-24 10:03:00 | BioMarin Stock Rises on Earnings Beat

2019-10-24 09:30:01 | HZNP or BMRN: Which Is the Better Value Stock Right Now?

2019-10-24 05:56:50 | Edited Transcript of BMRN earnings conference call or presentation 23-Oct-19 8:30pm GMT

2019-10-23 17:55:09 | BioMarin Pharmaceutical BMRN Surpasses Q3 Earnings and Revenue Estimates

2019-10-23 16:05:00 | BioMarin Announces Third Quarter 2019 Financial Results

2019-10-23 07:54:59 | The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

2019-10-22 11:32:03 | Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

2019-10-20 08:08:45 | The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

2019-10-19 09:14:52 | BioMarin Pharmaceutical NASDAQ:BMRN Is Carrying A Fair Bit Of Debt

2019-10-18 18:23:43 | BioMarin Pharmaceutical Inc. BMRN: Hedge Funds Fumbled the Ball

2019-10-17 10:41:00 | 4 Biotech Stocks That Are Set to Rally, Analyst Says

2019-10-16 10:33:02 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth

2019-10-09 08:31:00 | BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

2019-10-07 08:31:00 | BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

2019-10-01 17:10:41 | It's not just Google: 'Fierce' competition for tech talent is pushing median salaries past $200K at many Silicon Valley companies

2019-10-01 08:30:00 | BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

2019-09-30 14:52:13 | Investors flee Biotech ETFs as they Lag Bull Market

2019-09-30 11:00:00 | Healthcare: Political Uncertainties Have Weighed on the Sector

2019-09-27 21:39:00 | Biotech Roundtable: How to Invest in Medicine’s Future

2019-09-27 07:56:12 | The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

2019-09-26 08:31:00 | BioMarin, Pioneer in Phenylketonuria PKU Therapies, Submits Clinical Trial Application CTA in U.K. for Investigational Gene Therapy for PKU

2019-09-20 13:10:14 | Gilead, AbbVie Are Innovative, but May Be Underappreciated

2019-09-15 15:28:47 | Stocks That Fell to 3-Year Lows in the Week of Sept. 13

2019-09-13 08:12:56 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Overpaying Its CEO?

2019-09-09 16:05:00 | BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

2019-08-31 09:31:01 | BioMarin BMRN Down 7.3% Since Last Earnings Report: Can It Rebound?

2019-08-28 08:30:00 | BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

2019-08-14 12:06:57 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Trading At A 31% Discount?

2019-08-13 07:00:00 | The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook

2019-08-08 16:29:20 | 6 Underperforming Stocks in Gurus' Portfolios

2019-08-08 10:33:02 | Sarepta SRPT Q2 Loss Widens Y/Y, Golodirsen Nears Approval

2019-08-06 10:45:00 | BioMarin's Roller Coaster Continues

2019-08-03 08:54:04 | Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-02 11:23:36 | Biomarin Pharmaceutical Inc BMRN Q2 2019 Earnings Call Transcript

2019-08-02 10:52:02 | BioMarin BMRN Shares Down on Q1 Earnings & Sales Miss

2019-08-02 09:15:00 | BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried

2019-08-01 18:05:10 | BioMarin Pharmaceutical BMRN Lags Q2 Earnings and Revenue Estimates